Consistent with our previous work, mice treated with PancVAX delivered in combination with a STING agonist ADU-S100 and dual ICIs, anti–PD-1 and anti–CTLA-4 antibodies, displayed a significant improvement in the control of early tumor growth compared with vaccine alone or ICIs alone (Figure 1A). This evidence concerns the gene CTLA4 and neoplasm.